View in EDS PDF Full Text

ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.

Saved in:
Bibliographic Details
Title: ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.
Authors: Megino-Luque C; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Sisó P; Oncologic Pathology Group, Department of Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain., Mota-Martorell N; Metabolic Physiopathology Group, Department of Experimental Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain., Navaridas R; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain., de la Rosa I; Oncologic Pathology Group, Department of Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain., Urdanibia I; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain., Albertí-Valls M; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Santacana M; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Scientific and Technical Service of Immunohistochemistry, Biomedical Research Institute of Lleida (IRBLleida), Hospital Universitari Arnau de Vilanova, Lleida, Spain., Pinyol M; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain., Bonifaci N; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain., Macià A; Oncologic Pathology Group, Department of Experimental Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain., Llobet-Navas D; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain., Gatius S; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain., Matias-Guiu X; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Spain., Eritja N; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Oncologic Pathology Group, Department of Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.
Source: Molecular oncology [Mol Oncol] 2022 Jun; Vol. 16 (11), pp. 2235-2259. Date of Electronic Publication: 2022 Mar 02.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35167193
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Megino-Luque+C%22">Megino-Luque C</searchLink>; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Sisó+P%22">Sisó P</searchLink>; Oncologic Pathology Group, Department of Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Mota-Martorell+N%22">Mota-Martorell N</searchLink>; Metabolic Physiopathology Group, Department of Experimental Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Navaridas+R%22">Navaridas R</searchLink>; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22de+la+Rosa+I%22">de la Rosa I</searchLink>; Oncologic Pathology Group, Department of Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Urdanibia+I%22">Urdanibia I</searchLink>; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Albertí-Valls+M%22">Albertí-Valls M</searchLink>; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Santacana+M%22">Santacana M</searchLink>; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Scientific and Technical Service of Immunohistochemistry, Biomedical Research Institute of Lleida (IRBLleida), Hospital Universitari Arnau de Vilanova, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Pinyol+M%22">Pinyol M</searchLink>; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Bonifaci+N%22">Bonifaci N</searchLink>; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Macià+A%22">Macià A</searchLink>; Oncologic Pathology Group, Department of Experimental Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Llobet-Navas+D%22">Llobet-Navas D</searchLink>; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Gatius+S%22">Gatius S</searchLink>; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Matias-Guiu+X%22">Matias-Guiu X</searchLink>; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Eritja+N%22">Eritja N</searchLink>; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Oncologic Pathology Group, Department of Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101308230%22">Molecular oncology</searchLink> [Mol Oncol] 2022 Jun; Vol. 16 (11), pp. 2235-2259. <i>Date of Electronic Publication: </i>2022 Mar 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22John+Wiley+%26+Sons%2C+Inc%22">John Wiley & Sons, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101308230 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1878-0261 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215747891%22">15747891 </searchLink><i>NLM ISO Abbreviation: </i>Mol Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35167193
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/1878-0261.13193
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2235
    Titles:
      – TitleFull: ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Megino-Luque C
      – PersonEntity:
          Name:
            NameFull: Sisó P
      – PersonEntity:
          Name:
            NameFull: Mota-Martorell N
      – PersonEntity:
          Name:
            NameFull: Navaridas R
      – PersonEntity:
          Name:
            NameFull: de la Rosa I
      – PersonEntity:
          Name:
            NameFull: Urdanibia I
      – PersonEntity:
          Name:
            NameFull: Albertí-Valls M
      – PersonEntity:
          Name:
            NameFull: Santacana M
      – PersonEntity:
          Name:
            NameFull: Pinyol M
      – PersonEntity:
          Name:
            NameFull: Bonifaci N
      – PersonEntity:
          Name:
            NameFull: Macià A
      – PersonEntity:
          Name:
            NameFull: Llobet-Navas D
      – PersonEntity:
          Name:
            NameFull: Gatius S
      – PersonEntity:
          Name:
            NameFull: Matias-Guiu X
      – PersonEntity:
          Name:
            NameFull: Eritja N
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2022 Jun
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1878-0261
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Molecular oncology
              Type: main
ResultId 1